Antiseptic cap

Information

  • Patent Grant
  • 12076521
  • Patent Number
    12,076,521
  • Date Filed
    Friday, September 18, 2020
    4 years ago
  • Date Issued
    Tuesday, September 3, 2024
    2 months ago
Abstract
An antiseptic dead-end cap includes a base having first and second sides, a first annular wall extending from the first side of the base, a cylindrical center plug extending from the first side of the base, and a second annular wall extending from the second side of the base. The first annular wall has an outer and an inner surface. The cylindrical center plug has an outer and an inner surface, and is positioned within the first annular wall to form an annular chamber. The second annular wall has an outer and an inner surface, and defines a second chamber having an open end. The second chamber is further defined by the inner surface of the cylindrical center plug. An antiseptic material is on at least one of the first annular wall inner surface, second annular wall inner surface, second annular wall outer surface, and cylindrical center plug outer surface.
Description
BACKGROUND
Technical Field

The present invention relates to an antiseptic cap, and more particularly, to an antiseptic dead-end cap for a medical connector.


Background Art

Catheters are widely used to treat patients requiring a variety of medical procedures. Catheters can either be acute, or temporary, for short-term use or chronic for long-term treatment. Catheters are commonly introduced into central veins (such as the vena cava) from peripheral vein sites to provide access to a patient's vascular system.


In an IV dispensing system, a luer connector, e.g., a male luer connector, can have a first end and a second end. The first end of the male luer connector can be connected to a fluid line that is connected to a fluid source, such as an IV bag filled with fluid. The second end of the male luer connector can be removably attached to a first end of a female needleless luer connector. The second end of the female needleless luer connector can be attached to a catheter that has been introduced into a patient.


When the male luer connector and the female needleless luer connector are attached to each other, fluid from the IV bag can flow into the patient. These connectors are often separated from each other at various times, for example, when a patient needs to use restroom facilities. When the connectors are disengaged from each other, the connectors are exposed and are prone to contamination. Current procedures to reduce contamination of the connectors involve swabbing the connectors with a disinfection. These procedures are prone to human error and are often not implemented. Furthermore, when a male luer connector is disengaged from a female needleless connector, there is no standard manner in which to store and protect the male luer connector until it is reattached to the female connector.


SUMMARY

The present invention relates to an antiseptic dead-end cap for use with a connector that includes a base having first and second sides, a first annular wall extending from the first side of the base, a cylindrical center plug extending from the first side of the base, and a second annular wall extending from the second side of the base. The first annular wall has an outer surface and an inner surface. The cylindrical center plug has an outer surface and an inner surface, and is positioned within the first annular wall to form an annular chamber. The second annular wall has an outer surface and an inner surface, and defines a second chamber having an open end. An antiseptic material is on at least one of the inner surface of the first annular wall, the inner surface of the second annular wall, the outer surface of the second annular wall, and the outer surface of the cylindrical center plug.


The present invention further relates to an antiseptic dead-end cap for use with a connector that includes a base having first and second sides, a male connector portion extending from the first side of the base and configured to be connectable to a female luer, and a female connector portion extending from the second side of the base and configured to be connectable to a male luer. An antiseptic material is on at least a portion of the male luer connector portion or the female luer connector portion.


In some aspects, the male connector portion includes a first annular wall extending from the first side of the base and having an outer surface and an inner surface, and a cylindrical center plug extending from the first side of the base. The cylindrical center plug has an outer surface and an inner surface, and is positioned within the first annular wall to form an annular chamber. In such aspects, the female connector portion includes a second annular wall extending from the second side of the base, has an outer surface and an inner surface, and defines a second chamber having an open end.


In some aspects, the antiseptic material is a metal, while in other aspects, the antiseptic material can be an alcohol.


In other aspects, the first annular wall includes one or more threads. In still another aspect, the second annular wall includes one or more threads.


In yet another aspect, the antiseptic material is formed in at least one of the inner surface of the first annular wall, the inner surface of the second annular wall, the outer surface of the second annular wall, and the outer surface of the cylindrical center plug.





BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present invention, reference is made to the following Detailed Description of the Invention, considered in conjunction with the accompanying drawings, in which:



FIG. 1 is a cross-sectional view of an antiseptic cap assembly engaged to a luer connector according to the present invention;



FIG. 2 is a perspective view of a sealed antiseptic cap assembly;



FIG. 3 is an exploded perspective view showing the antiseptic cap assembly of FIG. 1 and a luer connector;



FIG. 4 is a perspective view of the antiseptic cap assembly of FIG. 1 engaged to a luer connector;



FIG. 5 is a cross-sectional view showing an antiseptic cap assembly, wherein a cap has an outer wall;



FIG. 6 is a cross-sectional view showing an antiseptic cap assembly, wherein the cap includes a center insert;



FIG. 7 is a cross-sectional view showing an antiseptic cap assembly, wherein the cap includes a center plug;



FIG. 8 is a cross-sectional view showing an antiseptic cap assembly, wherein a cap holder includes an inner-facing flange;



FIG. 9 is a cross-sectional view showing an antiseptic cap assembly, wherein a center plug is provided and the cap holder includes an inner-facing flange;



FIG. 10 is a cross-sectional view showing an antiseptic cap assembly, wherein a cap includes an annular portion without threads;



FIG. 11 is a cross-sectional view showing an antiseptic cap assembly that includes an antiseptic chamber;



FIG. 12 is a perspective view of the antiseptic cap assembly shown in FIG. 11;



FIG. 13 is a perspective view showing an antiseptic cap assembly, wherein a cap holder includes retainers;



FIG. 14 is a cross-sectional view, taken along section lines 14-14 and looking in the direction of the arrows, of the antiseptic cap assembly shown in FIG. 13;



FIG. 15 is a cross-sectional view, taken along section lines 15-15, of the antiseptic cap assembly shown in FIG. 13;



FIG. 16 is a cross-sectional view showing an antiseptic cap assembly that includes a ratchet assembly;



FIG. 17 is an exploded view of the antiseptic cap assembly shown in FIG. 16 and a luer connector;



FIG. 18 is a partially cut away perspective view of the antiseptic cap assembly shown in FIG. 16 showing the ratchet assembly;



FIG. 19 is a perspective view showing an antiseptic cap assembly without a cap holder;



FIG. 20 is a cross-sectional view showing the antiseptic cap assembly of FIG. 19 having hydrophobic and hydrophilic sections;



FIG. 21 is a perspective view showing an antiseptic cap assembly, wherein a cap holder has a flange with a recess for receiving a line;



FIG. 22 is a cross-sectional view showing an antiseptic cap assembly, wherein a plug is supported by an arm;



FIGS. 23-27 are perspective views showing an antiseptic cap assembly with various fastening mechanisms;



FIG. 28 is a perspective view of an antiseptic dead-end cap;



FIG. 29 is a front view of the antiseptic dead-end cap;



FIG. 30 is a side view of the antiseptic dead-end cap;



FIG. 31 is another perspective view of the antiseptic dead-end cap;



FIG. 32 is another perspective view of the antiseptic dead-end cap; and



FIG. 33 is a cross-sectional view of the antiseptic dead-end cap of FIG. 28 taken along line 33-33.





DETAILED DESCRIPTION

The present invention relates to an antiseptic cap assembly that engages a male end of a luer connector. It should be understood, however, that the teachings herein can be used with other types of medical connectors.



FIG. 1 is a cross-sectional view of an antiseptic cap assembly 10 engaged to a luer connector 12. A proximal end 14 of the luer connector 12 is attached to a fluid line 16 which is connected to a fluid source (not shown), such as a IV bag filled with fluid. The luer connector 12 includes an annular threaded portion 18 with internal threads 20 and a frustoconical male luer 22 positioned for insertion into a female luer connector (not shown). The male luer 22 includes a tip 26 having an opening 24 in fluid communication with the fluid line 16. The male luer 22 is arranged substantially concentrically within the threaded portion 18. As a result of their generally coaxial arrangement, the male luer 22 and the threaded portion 18 cooperate to form an annular space therebetween.


The antiseptic cap assembly 10 includes a cap holder 28 and a cap 30 sized to be positioned within the cap holder 28. The cap 30 includes a base 32 and an annular threaded portion 34 extending from the base 32. The base 32 could include a substantially flat surface 36 and an outer flange 38.


The threaded portion 34 of the cap 30 includes a rim 40 that defines an open end 42 (see FIG. 3). The base 32 closes the opposite end of the threaded portion 34. The threaded portion 34 could be formed with a tapered inner surface 46 that compliments the male luer 22 of the luer connector 12. In particular, the tapered inner surface 46 narrows from the rim 40 toward the base 32. The threaded portion 34 defines a chamber 48 (see FIG. 3) sized to receive the male luer 22. The threaded portion 34 includes external threads 50 for engaging the threads 20 of the luer connector 12. The external threads 50 and the threads 20 of the luer connector 12 cooperate with each other so as to allow the cap 30 to be securely threadedly connected to the luer connector 12 and also to allow relative movement between the cap 30 and the luer connector 12, as the cap 30 is rotated relative to the luer connector 12. The external threads 50 extend between the base 32 and the rim 40.


The configuration of the cap 30 is shown in perspective in FIG. 3. It should be noted that this configuration is exemplary. For example, the cap 30 could be configured without threads and sized to engage the luer connector 12 with a push-on friction fit, as will be described hereinafter.


The cap 30 could be made from an absorbent material. The cap 30 could be made from porous plastic, for example, a medical grade sintered porous plastic material which is available from Porex Corporation, based in Fairburn, GA Other suitable manufacturers of the porous plastic material include Filtrona, Genpore, and Thermopore. It is desirable that the material can absorb and retain a fluid such as an antiseptic fluid. It is also desirable that the material is sufficiently rigid to maintain its structure. It is also desirable that the material is compressible and that the absorbed fluid is released on compression. The porous plastic material could be made of any suitable polymer, such as polyethylene, polypropylene, nylon, etc.


The use of the porous plastic material is only exemplary. It will be understood that the cap 30 could be made from any other suitable material, such as bonded fiber, cotton, silicone, urethane, polyester, cellulose, etc. The material could be natural or synthetic.


The threaded portion 34 of the cap 30 could be coated or impregnated with an antiseptic fluid, an anticoagulant fluid, and/or an antimicrobial fluid. An example of a suitable antiseptic fluid is isopropyl alcohol. The concentration of the isopropyl alcohol could vary, and is preferably 70% v/v. The concentration of alcohol could be in a range from 20% to 100%. It will be understand that other materials could be used, such as other alcohols, including ethanol, propanol, and/or butanol, or iodine, hydrogen peroxide, chlorhexidine gluconate, chlorhexidine acetate, etc. The antiseptic, anticoagulant, and/or antimicrobial agent could be in liquid or solid form.


The cap holder 28 includes a cylindrically shaped sidewall 52 that defines a chamber 54 sized to receive the cap 30 and accommodate the male luer 22. The cap holder 28 could include an outer flange 56 that protrudes radially outwardly from a distal end 58 of the sidewall 52. The outer flange 56 defines an open end 60. The cap holder 28 could include a substantially flat surface 62 that defines the opposite, closed end. The cap holder 28 could be made from a thermoplastic elastomer, such as the thermoplastic elastomer sold by ExxonMobil under the trademark SANTOPRENE, or any other suitable material. The cap holder 28 could be made from a more rigid material, such as a high-density polyethylene. The cap holder 28 and the cap 30 could be bonded to each other, or attached to each other by any suitable method, such as by adhesive or by molding.


When the cap 30 is attached to the cap holder 28, a gap 64 may exist between the flange 38 of the cap 30 and the cap holder 28, and between the threaded portion 34 of the cap 30 and the cap holder 28. Also, the cap 30 is attached to the cap holder 28 such that the cap 30 rotates conjointly with the cap holder 28.


As shown in FIG. 2, the cap holder 28 could be sealed with a material, such as a film 66, a foil material or lid stock material, which can be attached to the flange 56 by any suitable method such as by adhesive or by conductive or inductive heat sealing techniques. A pull tab 68 could be provided to facilitate removal of the film 66 to provide access to the antiseptic cap 10.


Generally, the cap 30 may be hydrophobic. However, because the hydrophobic material could serve to inhibit or minimize an antiseptic fluid, such as isopropyl alcohol, from passing through the cap 30, it may be desirable to make at least a portion of the cap 30 hydrophilic. For example, it may be desirable to treat at least a portion of the cap 30 with a hydrophilic surfactant. In this manner, the hydrophilic portion could allow the alcohol to pass therethrough, whereas the hydrophobic portion could serve to inhibit or minimize an antiseptic fluid, such as isopropyl alcohol, from passing therethrough. In one embodiment, the threaded portion 34 could be treated with a hydrophilic surfactant whereas the base 32 could remain hydrophobic, so as to be resistant to an antiseptic fluid, such as alcohol. The hydrophobic section could also act as a plug to prevent IV fluid from leaking through the tubing to go past the cap 30.


Referring to FIG. 1, the antiseptic cap assembly 10 is shown attached to the luer connector 12 such that the threaded portion 34 of the cap 30 mates with the threads 20 of the luer connector 12 and the base 32 is positioned adjacent the opening 24 of the male luer 22. Also, in this position, the inner surface 46 of the threaded portion 34 is adjacent the male luer 22 and the male luer 22 compresses the cap 30 to release at least a portion of the antiseptic fluid to disinfect the luer connector 12. The antiseptic cap assembly 10 can be allowed to remain attached to the luer connector 12 for any suitable period of time. When the antiseptic cap assembly 10 is attached to the luer connector 12, as shown in the perspective view of FIG. 4, the luer connector 12 is exposed to the antiseptic fluid.


The cap holder 28 could be configured to remain on the cap 30 after the antiseptic cap assembly 10 engages the luer connector 12. Alternatively, the cap holder 28 could be configured to be removably attached to the cap 30. For example, the cap holder 28 could be removed from the cap 30 after the antiseptic cap assembly 10 engages the luer connector 12.



FIG. 5 shows an antiseptic cap assembly, indicated generally as 110, that is sized to engage and disinfect the male luer 22. The antiseptic cap assembly 110 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 110 includes a cap holder 128 and a cap 130 sized to be positioned within the cap holder 128.


Cap 130 includes an annular sidewall 111 extending from an outer flange 138 and substantially concentric with the threaded portion 134. When the cap holder 128 is used, the annular sidewall 111 is positioned proximate an outer surface of the cap holder 12. When the antiseptic cap assembly 110 is attached to the luer connector 12, the annular sidewall 111 bears against the outer surface of the threaded portion 18 of the luer connector 12. The annular sidewall 111 can be made from porous plastic like the remainder of the cap 130 or any other suitable material. The annular sidewall 111 covers and protects the outer surface of the threaded portion 18 of the luer connector 12. The annular sidewall 111 may contain antiseptic fluid and release at least a portion of an antiseptic fluid.



FIG. 6 shows an antiseptic cap assembly, indicated generally as 210, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 210 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 210 includes a cap holder 228 and a cap 230 sized to be positioned within the cap holder 228.


Cap 230 includes a center insert 211 that is integrally connected therewith. Alternatively, the cap 230 and the center insert 211 could be separate components. The center insert 211 may be made from porous plastic like the remainder of the cap 230 or any other suitable material, and may contain antiseptic fluid and release at least a portion of an antiseptic fluid. The center insert 211 could be treated with a hydrophilic surfactant, or otherwise made hydrophilic.


The center insert 211 protrudes from a base 232 of the cap 230 and is positioned within a threaded portion 234 of the cap 230. The center insert 211 has a distal end 213 that may have angled edges 215, thereby giving the center insert 211 a generally trapezoidal shape. The center insert 211 could define other shapes such as conical, square, rectangle, etc.


When the cap 230 is attached to a luer connector 12, the center insert 211 is positioned within the opening 24 formed in the male luer 22 and allows the antiseptic fluid to enter the male luer 22 to apply the antiseptic fluid to the inner tip 26 of the male luer 22.



FIG. 7 shows an antiseptic cap assembly, indicated generally as 310, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 310 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-3, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 310 includes a cap holder 328 and a cap 330 sized to be positioned within the cap holder 328.


A sealing mechanism, such as a center plug 311, is sized to extend from a base 332 of the cap 330 and is sized to be positioned within the threaded portion 334 of the cap 330. The cap 330 and the center plug 311 could be separate components as shown or, alternatively, the cap 330 and the center plug 311 could be integrally formed. Alternatively, the center plug 311 could be an extension of the cap holder 328 molded in.


The center plug 311 has a distal end 313 that may have angled edges 315, thereby giving the center plug 311 a generally trapezoidal shape. The center plug 311 could define other shapes such as conical, square, rectangle, etc.


The center plug 311 bears against the opening 24 formed in the male luer 22 to prevent the antiseptic fluid from entering the male luer 22. The center plug 311 extends a distance from the base 332 sufficient to engage the opening 24 in the male luer 22 before the threaded portion 334 of the cap 330 is compressed by the male luer 22, to seal the opening 24 in the male luer 22.


The center plug 311 could be made of a non-porous material, such as rubber, or any other suitable material. The center plug 311 could be made of porous plastic and left in a hydrophobic state, i.e., not treated with a surfactant like the threaded portion 334 of the cap 330, thereby inhibiting or minimizing antiseptic fluid from passing therethrough and into the opening 24 formed in the male luer 22. In this manner, the center plug 311 serves to limit or prevent alcohol from entering the fluid line 316 of the luer connector 312. Also the center plug 311 could act as a plug to prevent IV fluid from dripping out of the line.


The configuration of the sealing mechanism is only exemplary. It will be understood that the present invention could employ other sealing mechanisms. For example, the sealing mechanism could be a center pin (not shown) sized to extend further into the opening 24 formed in the male luer 22 than the center plug 311. The center plug 311 may extend past the threads on the threaded portion 324 and inserted prior to thread engagement.



FIG. 8 shows an antiseptic cap assembly, indicated generally as 410, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 410 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 410 includes a cap holder 428 and a cap 430 sized to be positioned within the cap holder 428.


The cap holder 428 includes an inner-facing flange 411 that may form a protective seal that closes off the interior of the cap holder 428 when the antiseptic cap assembly 410 is engaged to the luer connector 12. The inner flange 411 extends radially inward from a distal end 458 of the sidewall 452 of the cap holder 428. When the antiseptic cap assembly 410 is engaged to the luer connector 12, the inner-facing flange 411 of the cap holder 428 may contact the threaded portion 18 of the luer connector 12 to seal the interior of the cap holder 428.


The inner-facing flange 411 of the cap holder 428 may provide a physical barrier to the ingress of pathogens, dust or other contaminants into the cap holder 428. The inner-facing flange 411 may serve to retain at least a portion of the antiseptic fluid from the antiseptic cap assembly 410 from leaking out. The inner-facing flange 411 may prevent evaporation of at least a portion of the antiseptic fluid that is retained.


The configuration of the cap holder 428 could vary. For example, the cap holder 428 could include an outer flange (not shown), such as the outer flange 56 (FIG. 1) that protrudes radially outwardly from the distal end 458 of the sidewall 452, as well as the inner-facing flange 411 that protrudes radially inward from the distal end 458 of the sidewall 452.



FIG. 9 shows an antiseptic cap assembly, indicated generally as 510, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 510 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 510 includes a cap holder 528 and a cap 530 sized to be positioned within the cap holder 528.


The antiseptic cap assembly 510 includes a center plug 511, such as the center plug 311 shown in FIG. 7. In addition, the cap holder includes an inner-facing flange 513, such as the flange 411 shown in FIG. 8.


It should be understood that various features of various embodiments disclosed herein could be used together without departing from the spirit or scope of the present invention.



FIG. 10 shows an antiseptic cap assembly, indicated generally as 610, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 610 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 610 includes a cap holder 628 and a cap 630 sized to be positioned within the cap holder 628.


The cap 630 includes an annular portion 611 extending from a base 632. The annular portion 611 is configured without threads but is sized to engage the luer connector 12 with a push-on friction fit. The antiseptic cap assembly 610 could be removed by pulling out of the luer connector 12.


The annular portion 611 of the cap 630 could be configured such that the inner surface contacts the male luer 22 and is compressed by the male luer 22 to release antiseptic fluid when the cap 630 is pushed on to the male luer 22. The outer surface of the annular portion 611 could also contact against the inner threads 18 of the threaded portion 18 of the male luer 22 and could also release antiseptic fluid on this side. Alternatively, the annular portion 611 could be configured to avoid contact with the threads 20 of the luer connector 12. The annular portion 611 does not need to be tapered as shown.



FIGS. 11 and 12 show an antiseptic cap assembly, indicated generally as 710, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 710 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-3, unless stated otherwise. The antiseptic cap assembly 710 includes an antiseptic chamber 715 and a cap 730.


The cap 730 includes an annular portion 711 extending from a base 732. The annular portion 711 is configured and sized to engage the luer connector 12 with a push-on friction fit.


The antiseptic chamber 715 is attached to the base 732 of the cap 730 and is formed by a continuous sidewall 713 and an end wall 723. The sidewall 713 includes an inner flange 717 that extends radially inward from the sidewall 713. The flange 717 defines an open end 721.


The base 732 of the cap 730 is keyed to the antiseptic chamber 715. The base 732 of the cap 730 is positioned within the antiseptic chamber 715 such that the outer flange 738 of the base 732 is captured in the antiseptic chamber 715 by the inner flange 717 of the antiseptic chamber 715 which extends over the base 732. The base 732 closes off the disinfectant chamber 715 and the annular portion 711 of the cap 730 is in contact with the inner flange 717 of the antiseptic chamber 715. The cap 730 could be attached to the antiseptic chamber 715 such that the cap 730 rotates conjointly with the antiseptic chamber 715. In one embodiment, the base 732 of the cap 730 does not need to be keyed to the antiseptic chamber 715 in a push-on design.


The antiseptic chamber 715 can include an absorbent material 725, such as a pad, sponge, or elastomeric foam, configured to retain an antiseptic fluid. The absorbent material 725 could be wetted or soaked with the antiseptic fluid. The absorbent material 725 could be deformable. The cap 730 could be made from a porous plastic material that serves as a carrier for the transfer of antiseptic fluid from the disinfectant chamber 715. When the cap holder 728 is compressed, the absorbent material 725 releases at least a portion of the antiseptic fluid. The fluid can then flow through the base 732 and along the annular portion 711 to be delivered to the male luer 22. FIG. 12 shows a perspective view of the antiseptic cap assembly 710.


It will be understood that the present invention could employ other mechanisms that involve pushing on a component of an antiseptic cap assembly to activate or release the antiseptic fluid.



FIGS. 13-15 show an antiseptic cap assembly, indicated generally as 810, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 810 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-3, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 810 includes a cap holder 828 and a cap 830 sized to be positioned within the cap holder 828.


The cap 830 includes an annular portion 811 extending from a base 832. The annular portion 811 is configured without threads and sized to engage the luer connector 12 with a push-on friction fit. The antiseptic cap assembly 810 could be removed by pulling out of the luer connector 12.


The cap holder 828 includes retainers 813 that serve to retain or secure the cap 830 on the luer connector 12. The retainers 813 include a pair of shoulders 815, 817 that extend perpendicularly from opposite sides of the outer flange 856 of the cap holder 828 and a pair of arms 823, 825 that extend radially inward from the shoulders 815, 817.


When the antiseptic cap assembly 810 is engaged to the luer connector 12, the arms 823, 825 of the retainers 813 extend over the male luer 22 to retain the cap 830. The retainers 813 could be made from a thermoplastic elastomer, such as SANTOPRENE, or any other suitable material. The retainers 813 could be made from a flexible material.


The cap holder 828 may include gripping areas defined by a recessed portion 827 (FIGS. 13 and 15) and a recessed portion 829 (FIGS. 13 and 15) on opposite sides of the outer sidewall 852. The recessed portions 827, 829 are configured for gripping the cap 830 to attach the cap 830 to the male luer 22.



FIGS. 16-18 show an antiseptic cap assembly, indicated generally as 910, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 910 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 910 includes a cap holder 928 and a cap 930 inserted within the cap holder 928. This embodiment includes a mechanism to prevent overtightening of the cap 930 on the male luer 22 which could damage the male luer 22. This is addressed with a ratchet assembly.


The cap 930 includes a base 932 and an annular threaded portion 934 extending from the base 932. The base 932 includes an outer flange 938 with a plurality of teeth 911 (see FIGS. 17 and 18), along the outer perimeter that allows for rotation in only one direction. Alternatively, it could be configured to allow for rotation in both directions by angling both surfaces of the teeth. The teeth 911 have angled faces 912 and generally perpendicular faces 914.


The cap holder 928 includes a retaining mechanism for retaining the cap 930 in the cap holder 928. The retaining mechanism could include a first protrusion 913 that extends from one section of the sidewall 952 of the cap holder 928, and a second protrusion 915 that extends from an opposite section of the sidewall 952 of the cap holder 928. The first and second protrusions 913, 915 are configured to extend over the base 932 of the cap 930. Alternatively, the retaining mechanism could include a single ring around the interior of the cap holder 928.


The cap holder 928 includes a plurality of teeth 917 that mate with the teeth 911 to form a ratchet mechanism. The teeth 917 interact with the teeth 911 to allow the cap 930 to rotate in the cap holder 928 in only one direction, and have angled faces 916 and generally perpendicular faces 918, like the teeth 911 of the base 932. Alternatively, it could be configured to allow for rotation in both directions.


The ratchet mechanism provides an audible or a tactile feedback to indicate that the antiseptic cap assembly 910 is properly secured. Also, the ratchet mechanism could limit torque to prevent damage to the luer connector 12 or to the cap 930. The cap 930 is threaded on the male luer 22 in accordance with other embodiments of the cap 930. If the cap 930 is turned beyond the limit of the threads, instead of damaging the male luer 22, the cap 930 will slide with respect to the cap holder 928, the angled teeth 911, 917 of the base 932 of the cap 930 and the cap holder 930 respectively sliding past one another to prevent further tightening of the cap 930 onto the male luer 22. When removing the cap 930 from the male luer 22, the generally perpendicular faces 914, 918 engage and do not permit sliding.



FIG. 19 shows an antiseptic cap assembly, indicated generally as 1010, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 1010 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise.


The cap 1030 is used without a cap holder. The cap 1030 includes a base 1032 and an annular threaded portion 1034 extending from the base 1032. Antiseptic fluid can be associated with the interior surface of the annular threaded portion 1034.


The configuration of the cap 1030 is only exemplary. For example, the cap 1030 could be configured without threads and sized to engage the luer connector 12 with a push-on friction fit. Likewise, the cap 1030 could also include a sidewall, like that shown in FIG. 5.



FIG. 20 shows an antiseptic cap assembly, indicated generally as 1110, that is sized to engage and disinfect a male luer. The antiseptic cap assembly 1110 operates and is constructed in manners consistent with the antiseptic cap assembly 1010 shown in FIG. 18, unless stated otherwise.


At least a portion of the cap 1130 could be treated with a hydrophilic surfactant, or otherwise made hydrophilic. The threaded portion 1134 could be treated with a hydrophilic surfactant whereas the base 1132 could remain hydrophobic, so as to be resistant to and non-absorbent of an antiseptic fluid.


A center plug 1111 could bear against the opening 24 formed in the male luer 22 to prevent the antiseptic fluid from entering the male luer 22. The center plug 1111 could be made of porous plastic and left in a hydrophobic state, thereby inhibiting or minimizing antiseptic fluid from passing therethrough and into the opening 24 formed in the male luer 22. The hydrophobic section could also act as a plug in the IV line to prevent ingress of antiseptic fluid or to stop leakage of IV fluid.



FIG. 21 shows an antiseptic cap assembly, indicated generally as 1210, that is sized to engage and disinfect a male luer 22. The antiseptic cap assembly 1210 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-4, unless stated otherwise.


The cap holder 1228 has a notch 1211 in an outer flange 1256 that is configured to attached to a supporting surface, such as a fluid line 1213. As shown, the cap holder 1228 has a plurality of ribs 1215 extending along a sidewall 1252 from one end 1217 of the cap holder 1228 to the opposite end 1219 of the cap holder 1228. The ribs 1215 facilitate gripping of the cap holder 1228.



FIG. 22 shows an antiseptic cap assembly, indicated generally as 1310, that is sized to engage and disinfect a male luer. The antiseptic cap assembly 1310 operates and is constructed in manners consistent with the antiseptic cap assembly 10 shown in FIGS. 1-3, unless stated otherwise. Like the antiseptic cap assembly 10, the antiseptic cap assembly 1310 includes a cap holder 1328 and a cap 1330 sized to be positioned within the cap holder 1328.


A sealing mechanism, such as a center plug 1311, is sized to extend from the cap holder 1328 through the base 1332 and is sized to be positioned within the threaded portion 1334 of the cap 1330. As such, the center plug 1311 is made of a non-porous material such as SANTOPRENE, or any other suitable material. In particular, the center plug 1311 includes an arm 1313 with one end 1315 extending from the base 1332, and a sphere 1317 attached to an opposite end 1319 of the arm 1313. The sphere 1317 is configured to bear against the opening 24 formed in the male luer 22 to limit the distance that the antiseptic fluid can travel into the male luer 22. Alternatively, the center plug 1311 could extend from the base 1332 and be made of another material such as rubber. The sphere 1317 could be replaced with a non-spherical device.


Any of the antiseptic cap assemblies 10, 110, 210, 310, 410, 510, 610, 710, 810, 910, 1010, 1110, 1210, and 1310 disclosed herein could be configured to be removably attached to a suitable surface (not shown), such as a IV bag, IV pump, or IV pole, etc., for use. For example, in FIG. 23, the substantially flat surface 62 of the cap holder 28 includes a clip 80 sized to removeably secure the antiseptic cap assembly 10 to a supporting surface (not shown), such as a IV bag. In FIG. 24, a hook 82 could be provided extending from the substantially flat surface 62 of the cap holder 28 and sized to removeably secure the antiseptic cap assembly 10 to a supporting surface (not shown).


In FIG. 25, a horseshoe-shaped clip 84 could be provided extending from the substantially flat surface 62 of the cap holder 28 and sized to releasably fasten an antiseptic cap assembly 10 to a supporting surface (not shown). The location of a fastening member could vary. For example, in FIG. 26, the sidewall 52 of the cap holder 28 includes a clip 86.


In FIG. 27, the end surface 62 of the cap holder 28 includes an adhesive 88 that could be covered by a release sheet 89. The adhesive 88 could be used to attach the antiseptic cap assembly 10 to a supporting surface, such as a IV pole. A pull tab 90 could be provided to remove the release sheet 89 to expose the adhesive 88.


Alternative fastening mechanisms could be provided. For example, the antiseptic cap assembly could include a ring (not shown).


The antiseptic cap assembly could be incorporated in kits with flush syringes, caps for treating a catheter or needleless connector, and line access devices, etc. The antiseptic fluid used could include an anticoagulant material, and/or an antimicrobial material. Examples of antiseptic fluid that could be used are disclosed in U.S. patent application Ser. No. 11/821,190, filed on Jun. 22, 2007, and Ser. No. 12/214,526, filed on Jun. 19, 2008. The entire disclosures of U.S. patent application Ser. Nos. 11/821,190 and 12/214,526 are incorporated herein by reference in their entirety.



FIG. 28 is a perspective view of a multifunction antiseptic dead-end cap 1410. The antiseptic dead-end cap 1410 includes a first portion 1412, e.g., a male connector portion, that connects to a female luer (not shown) and a second portion 1414, e.g., a female connector portion, that connects to a male luer (not shown). The male luer or the female luer may, respectively, be attached to a fluid source (not shown), such as an IV bag filled with fluid. For example, the male luer may be the male luer 22 illustrated in FIGS. 1 and 3-27 and described with respect thereto.


As shown in FIGS. 28-33, the first portion 1412 includes a first annular wall 1416 extending from a base 1418. The first annular wall 1416 includes one or more threads 1420 positioned on an interior wall of the first annular wall 1416. The threads 1420 of the first portion 1412 are configured to engage and cooperate with threads of a female luer to allow the dead-end cap 1410 to be securely threadedly connected to the female luer.


The first annular wall 1416 defines an open end 1422. The base 1418 closes the opposite end of the first annular wall 1416. A cylindrical center plug 1430 extends from the base 1418 in the direction of the first annular wall 1416 and is closed by an end wall 1432. The first annular wall 1416 and the cylindrical center plug 1430 are coaxial with one another and the cylindrical center plug 1430 is smaller in diameter than the first annular wall 1416. The first annular wall 1416, the base 1418, and the cylindrical center plug 1430 define a first chamber 1424 that is annular, accessible by the open end 1422, and sized to receive the female luer. When a female luer is inserted through the open end 1422 of the first portion 1412, the cylindrical center plug 1430 and the end wall 1432 are inserted into a portion of the female luer.


The second portion 1414 includes a second annular wall 1426 extending from the base 1418 opposite the direction of the first annular wall 1416, and forms an internal shoulder 1428 with the base 1418. The second annular wall 1426 has an open end 1434 and forms a second chamber 1436, while the cylindrical center plug 1430 and the end wall 1432 form a third chamber 1438. The second chamber 1436 and the third chamber 1438 are in fluidic communication, and the second chamber 1436 is accessible by the open end 1434. The second chamber 1436 is sized to receive a male luer.


One or more threads 1440 are positioned on an exterior wall of the second annular wall 1426. The threads 1440 are configured to engage and cooperate with threads of a male luer connector, such as luer connector 12 shown in FIG. 1. The threads 1440 and the threads of the male luer connector cooperate with each other so as to allow the dead-end cap 1410 to be securely threadedly connected to the male luer connector. The dead-end cap 1410 may include a plurality of external ridges 1442 provided on the first portion 1412 to facilitate gripping of the dead-end cap 1410 during handling and connecting with a connector.


Using the male luer connector 12 shown in FIG. 1 as an example, when the male luer connector 12 engages the second portion 1414, the male luer 22 of the male luer connector 12 is inserted into the open end 1434 and into the second chamber 1436. As the threads 20 of the male luer connector 12 engage the threads 1440 of the second portion 1414, the male luer 22 traverses further into the second chamber 1436 and may traverse into the third chamber 1428. The second annular wall 1426 could be formed with a tapered shape that compliments the male luer 22 of the luer connector 12. In such a configuration, the second annular wall 1426 may narrow from the open end 1434 to the base 1418.


As mentioned above, the antiseptic dead-end cap 1410 has a dual operability wherein it is configured to not only attach to a male luer connector, but also a female luer connector. Generally, a female luer connector can include a circumferential wall that defines a chamber and has external threads. When attaching the dead-end cap 1410 to a female luer connector, the circumferential wall of the female luer connector is inserted through the open end 1422 and into the first chamber 1424, such that the cylindrical center plug 1420 is inserted into the circumferential wall of the female luer connector. The dead-end cap 1410 can be twisted so that the one or more threads 1420 engage the female luer connector, securing the dead-end cap 1410 with the female luer connector.



FIG. 33 is a cross-section of the multifunction antiseptic dead-end cap 1410 of FIG. 28 taken along line 33-33. FIG. 33 shows the configuration of the dead-end cap 1410 in greater detail. It should be noted that this configuration is exemplary. For example, the dead-end cap 1410 could be configured without the first portion threads 1420 and/or the second portion threads 1440. In such a configuration, the first annular wall 1416 and the cylindrical center plug 1430 may be sized to engage a female luer connector with a push-on friction fit. Similarly, the second annular wall 1426 may be sized to engage a male luer connector with a push-on friction fit.


The dead-end cap 1410 functions to cap a male luer connector and/or a female luer connector so that fluid does not leak from a fluid source. The dead-end cap 1410 may be used for a temporary disconnect of male and female luers so that they do not warrant disposal.


While the antiseptic cap disclosed herein includes male and female connector portions, it could also be provided having just a male or just a female portion. In an arrangement where the antiseptic dead-end cap 1420 includes only a male connector portion, the dead-end cap 1420 could include the base 1418, the first annular wall 1416 extending from the base 1418, the cylindrical center plug 1430 extending from the base 1418 in the direction of the first annular wall 1416 and closed by the end wall 1432, and the plurality of threads 1420. The second annular wall 1426, and the female side of the cap can be eliminated. In an arrangement where the antiseptic dead-end cap 1420 includes only a female connector portion, the dead-end cap 1420 could include the base 1418, the second annular wall 1426 and the threads 1440, with the base 1418 and the second annular wall 1426 defining the second chamber 1436. The first annular wall 1416, and the cylindrical center plug 1430 could be eliminated.


Portions of the antiseptic dead-end cap 1410, such as an inner surface of the first annular wall 1416, the plurality of threads 1420, an outer surface of the second annular wall 1426, an inner surface of the second annular wall 1426, and the second portion threads 1440, could be coated or impregnated with an antiseptic fluid, an anticoagulant fluid, and/or an antimicrobial fluid. An example of a suitable antiseptic fluid is isopropyl alcohol. The concentration of the isopropyl alcohol could vary, and is preferably 70%. The concentration of alcohol could be in a range from 20% to 100%. It will be understand that other materials could be used, such as other alcohols, including ethanol, propanol, and/or butanol, or iodine, hydrogen peroxide, chlorhexidine gluconate, chlorhexidine acetate, etc. The antiseptic, anticoagulant, and/or antimicrobial agent could be in liquid or solid form.


The antiseptic dead-end cap 1410 may be constructed of a material having a 40-60 durometer hardness value on a Shore A scale. The material may be a medium soft to medium hard rubber that is pliable and malleable for purposes of engagement with a luer.


Antiseptic Coatings


It is contemplated that the devices described herein can be coated with an antiseptic coating by any suitable technique such as immersion of the part into an antiseptic solution, by spray coating the part with the antiseptic solution, by blending the antiseptic solution or material into the polymeric material used to fabricate the device.


A quantity of physiological, antimicrobial metal compound is added to the resin for direct molding of an article. Physiological, antimicrobial metals are meant to include the precious metals, such as silver, gold and platinum, and copper and zinc. Physiological, antimicrobial metal compounds used herein include oxides and salts of preferably silver and also gold, for example: silver acetate, silver benzoate, silver carbonate, silver citrate, silver chloride, silver iodide, silver nitrate, silver oxide, silver sulfadiazine, silver sulfate, gold chloride and gold oxide. Platinum compounds such as chloroplatinic acid or its salts (e.g., sodium and calcium chloroplatinate) may also be used. Also, compounds of copper and zinc may be used, for example: oxides and salts of copper and zinc such as those indicated above for silver. Single physiological, antimicrobial metal compounds or combinations of physiological, antimicrobial metal compounds may be used.


Preferred physiological, antimicrobial metal compounds used in this invention are silver acetate, silver oxide, silver sulfate, gold chloride and a combination of silver oxide and gold chloride. The particles of the silver compounds are sufficiently able to be extracted to form a zone of inhibition to prevent and kill bacteria growth.


In another preferred form of the invention the devices herein are impregnated with triclosan and silver compounds or triclosan and chlorhexidine, or chlorhexidine gluconate, or chlorhexidine acetate.


It will be understood that the embodiments described herein are merely exemplary and that a person skilled in the art may make many variations and modifications without departing from the spirit and scope of the invention. All such variations and modifications are intended to be included within the scope of the invention as defined by the appended claims.

Claims
  • 1. An antiseptic cap comprising: a rigid housing comprising a housing bottom wall and a housing sidewall extending from the housing bottom wall at least partially surrounding an interior chamber and an opening into the interior chamber;a non-threaded interior surface portion extending at least partially along the housing sidewall from the opening and towards the bottom wall, the non-threaded interior surface portion being compressible and being configured to directly engage and securely attach the antiseptic cap to a medical device;an antiseptic liquid being positioned within the rigid housing; anda seal being removably attached to an outer surface of the rigid housing and extending over the interior chamber such that the antiseptic liquid is exposed upon removal of the seal.
  • 2. The antiseptic cap of claim 1, wherein the interior surface portion is separate from the rigid housing.
  • 3. The antiseptic cap of claim 1, wherein the interior surface portion is configured to attach to a threaded portion of the medical device.
  • 4. The antiseptic cap of claim 1, wherein the interior surface portion is configured to expand and receive the medical device when the antiseptic cap is securely attached to the medical device.
  • 5. The antiseptic cap of claim 1, wherein the interior surface portion is configured to securely attach to the medical device as the antiseptic cap is applied to the medical device in a direction along a longitudinal axis of the antiseptic cap.
  • 6. The antiseptic cap of claim 1, wherein the rigid housing further comprises a plurality of ribs configured to facilitate attachment of the antiseptic cap to the medical device, and wherein each of the plurality of ribs extend at least partially along an external surface of the housing sidewall.
  • 7. The antiseptic cap of claim 1, wherein the interior surface portion is configured to securely attach to the medical device, wherein the interior surface portion is separate from the rigid housing,wherein the interior surface portion is configured to expand and receive a threaded portion of the medical device when the antiseptic cap is securely attached to the medical device, andwherein the rigid housing further comprises a plurality of ribs configured to facilitate attachment of the antiseptic cap to the medical device, and wherein each of the plurality of ribs extend at least partially along an external surface of the housing sidewall.
  • 8. A combination of the antiseptic cap of claim 1 and the medical device.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/162,106, filed Oct. 16, 2018, which is a continuation of U.S. patent application Ser. No. 13/803,289, filed on Mar. 14, 2013, now U.S. Pat. No. 10,166,381, which is a continuation-in-part of U.S. patent application Ser. No. 13/113,777, filed on May 23, 2011, now U.S. Pat. No. 9,867,975, the entire disclosure of each of which is expressly incorporated herein by reference.

US Referenced Citations (768)
Number Name Date Kind
382297 Fry May 1888 A
559697 Tiugti et al. May 1896 A
877946 Overton Feb 1908 A
975939 William et al. Nov 1910 A
1445642 O'Neill Feb 1923 A
1793068 Dickinson Feb 1931 A
2098340 Henahan Nov 1937 A
2436297 Guarnaschelli Feb 1948 A
2457052 Le Clair Dec 1948 A
2771644 Martin Nov 1956 A
3262448 Ring et al. Jul 1966 A
3270743 Gingras Sep 1966 A
3301392 Eddingfield Jan 1967 A
3411665 Blum Nov 1968 A
3485416 Fohrman Dec 1969 A
3538950 Porteners Nov 1970 A
3595241 Sheridan Jul 1971 A
3604582 Boudin Sep 1971 A
3882858 Klemm May 1975 A
3977401 Pike Aug 1976 A
3977517 Kadlecik et al. Aug 1976 A
3987930 Fuson Oct 1976 A
3993066 Virag Nov 1976 A
4041934 Genese Aug 1977 A
4046889 Ondetti et al. Sep 1977 A
4052511 Cushman et al. Oct 1977 A
4053052 Jasper Oct 1977 A
4053651 Ondetti et al. Oct 1977 A
4078686 Karesh et al. Mar 1978 A
4095810 Kulle Jun 1978 A
4113751 Arnold Sep 1978 A
4129571 Ondetti et al. Dec 1978 A
4133441 Mittleman et al. Jan 1979 A
4154840 Ondetti et al. May 1979 A
4154960 Ondetti et al. May 1979 A
4192443 McLaren Mar 1980 A
4243035 Barrett Jan 1981 A
4264664 Kunz Apr 1981 A
4280632 Yuhara Jul 1981 A
4294370 Toeppen Oct 1981 A
4317446 Ambrosio et al. Mar 1982 A
4325368 Kaemmerer Apr 1982 A
4331783 Stoy May 1982 A
4335756 Sharp et al. Jun 1982 A
4337327 Stoy Jun 1982 A
4354490 Rogers Oct 1982 A
4369294 Stoy Jan 1983 A
4370451 Stoy Jan 1983 A
4379874 Stoy Apr 1983 A
4384589 Morris May 1983 A
4390016 Riess Jun 1983 A
4402691 Rosenthal et al. Sep 1983 A
4417890 Dennehey et al. Nov 1983 A
4420589 Stoy Dec 1983 A
4427126 Ostrowsky Jan 1984 A
4432764 Lopez Feb 1984 A
4432766 Bellotti et al. Feb 1984 A
4439184 Wheeler Mar 1984 A
4440207 Genatempo et al. Apr 1984 A
4444310 Odell Apr 1984 A
4446967 Halkyard May 1984 A
4447419 Quadro May 1984 A
4461368 Plourde Jul 1984 A
4461896 Portlock Jul 1984 A
4480940 Woodruff Nov 1984 A
4507111 Gordon et al. Mar 1985 A
4534764 Mittleman et al. Aug 1985 A
4559043 Whitehouse Dec 1985 A
4568675 Bush et al. Feb 1986 A
4585758 Huang et al. Apr 1986 A
4602042 Chantler et al. Jul 1986 A
4624664 Peluso et al. Nov 1986 A
4626545 Taub Dec 1986 A
4631188 Stoy Dec 1986 A
4642091 Richmond Feb 1987 A
4666057 Come et al. May 1987 A
4666427 Larsson et al. May 1987 A
4671306 Spector Jun 1987 A
4671412 Gatten Jun 1987 A
4681886 Haugwitz et al. Jul 1987 A
4692458 Ryan et al. Sep 1987 A
4692459 Ryan et al. Sep 1987 A
4703762 Rathbone et al. Nov 1987 A
4705790 Hubele et al. Nov 1987 A
4728075 Paradis Mar 1988 A
4728321 Chen Mar 1988 A
4738668 Bellotti et al. Apr 1988 A
4747502 Luenser May 1988 A
4748160 Bennion et al. May 1988 A
4752983 Grieshaber Jun 1988 A
4769013 Lorenz et al. Sep 1988 A
4778447 Velde et al. Oct 1988 A
4799926 Haber Jan 1989 A
4808158 Kreuzer et al. Feb 1989 A
4810241 Rogers Mar 1989 A
4811847 Reif et al. Mar 1989 A
4813933 Turner Mar 1989 A
4834271 Litwin May 1989 A
4874366 Zdeb et al. Oct 1989 A
4889255 Schiemann et al. Dec 1989 A
4894056 Bommarito Jan 1990 A
4898580 Crowley Feb 1990 A
4919658 Badia Apr 1990 A
4927019 Haber et al. May 1990 A
4941873 Fischer Jul 1990 A
4957637 Cornell Sep 1990 A
4963132 Gibson Oct 1990 A
4983161 Dadson et al. Jan 1991 A
4985017 Theeuwes Jan 1991 A
4989733 Patry Feb 1991 A
4991629 Ernesto et al. Feb 1991 A
4997371 Fischer Mar 1991 A
4999210 Solomon et al. Mar 1991 A
5002964 Loscalzo Mar 1991 A
5015238 Solomon et al. May 1991 A
5019096 Fox, Jr. et al. May 1991 A
5024657 Needham et al. Jun 1991 A
5025001 Loscalzo et al. Jun 1991 A
5026359 Burroughs Jun 1991 A
5031622 LaHaye Jul 1991 A
5033961 Kandler et al. Jul 1991 A
5049139 Gilchrist Sep 1991 A
5059186 Yamamoto et al. Oct 1991 A
5065783 Ogle, II Nov 1991 A
5071413 Utterberg Dec 1991 A
5129824 Keller Jul 1992 A
5143104 Iba et al. Sep 1992 A
5154920 Flesher et al. Oct 1992 A
5184742 DeCaprio et al. Feb 1993 A
5190534 Kendell Mar 1993 A
5195957 Tollini Mar 1993 A
5205820 Kriesel Apr 1993 A
5205821 Kruger et al. Apr 1993 A
5207706 Menaker May 1993 A
5212204 Keefer et al. May 1993 A
5240675 Wilk et al. Aug 1993 A
5242421 Chan Sep 1993 A
5242425 White et al. Sep 1993 A
5246011 Caillouette Sep 1993 A
5250550 Keefer et al. Oct 1993 A
D342134 Mongeon Dec 1993 S
5269771 Thomas et al. Dec 1993 A
5278192 Fung et al. Jan 1994 A
5297310 Cox et al. Mar 1994 A
5304130 Button Apr 1994 A
5324647 Rubens et al. Jun 1994 A
5330426 Kriesel et al. Jul 1994 A
5330899 Devaughn et al. Jul 1994 A
5337730 Maguire Aug 1994 A
5352410 Hansen et al. Oct 1994 A
5354267 Niermann et al. Oct 1994 A
5366505 Farber Nov 1994 A
5366997 Keefer et al. Nov 1994 A
5370614 Amundson et al. Dec 1994 A
5370640 Kolff Dec 1994 A
5375589 Bhatta Dec 1994 A
5380758 Stamler et al. Jan 1995 A
5405919 Keefer et al. Apr 1995 A
5407807 Markus Apr 1995 A
5409012 Sahatjian Apr 1995 A
5428070 Cooke et al. Jun 1995 A
5433705 Giebel et al. Jul 1995 A
5470307 Lindall Nov 1995 A
5471706 Wallock et al. Dec 1995 A
5496288 Sweeney Mar 1996 A
5485827 Zapol et al. Jun 1996 A
5525357 Keefer et al. Jun 1996 A
5536241 Zapol Jul 1996 A
5536258 Folden Jul 1996 A
5545614 Stamler et al. Aug 1996 A
5552115 Malchesky Sep 1996 A
5554127 Crouther et al. Sep 1996 A
5554135 Menyhay Sep 1996 A
5580530 Kowatsch et al. Dec 1996 A
5599352 Dinh et al. Feb 1997 A
5605696 Eury et al. Feb 1997 A
5607072 Rigney et al. Mar 1997 A
5620088 Martin et al. Apr 1997 A
5620427 Werschmidt et al. Apr 1997 A
5624402 Imbert Apr 1997 A
5628733 Zinreich et al. May 1997 A
5665077 Resen et al. Sep 1997 A
5685835 Brugger Nov 1997 A
5685866 Lopez Nov 1997 A
5688253 Lundquist Nov 1997 A
5694978 Heilmann et al. Dec 1997 A
5702017 Goncalves Dec 1997 A
5716339 Tanaka et al. Feb 1998 A
5722537 Sigler Mar 1998 A
5763409 Bayol et al. Jun 1998 A
5770645 Stamler et al. Jun 1998 A
5776116 Lopez Jul 1998 A
5782808 Folden Jul 1998 A
5792120 Menyhay Aug 1998 A
5797887 Rosen et al. Aug 1998 A
5810792 Fangrow, Jr. et al. Sep 1998 A
5814666 Green et al. Sep 1998 A
5820604 Fox et al. Oct 1998 A
5827244 Boettger Oct 1998 A
5839715 Leinsing Nov 1998 A
5902631 Wang et al. May 1999 A
5941857 Nguyen et al. Aug 1999 A
5947296 Castora Sep 1999 A
5951519 Utterberg Sep 1999 A
5954957 Chin-Loy et al. Sep 1999 A
5971972 Rosenbaum Oct 1999 A
D416086 Parris et al. Nov 1999 S
5989229 Chiappetta Nov 1999 A
5994444 Trescony Nov 1999 A
5996779 Klardie et al. Dec 1999 A
6041805 Gydesen et al. Mar 2000 A
6045539 Menyhay Apr 2000 A
6045623 Cannon Apr 2000 A
6059107 Nosted et al. May 2000 A
6068475 Stoyka, Jr. et al. May 2000 A
6071413 Dyke Jun 2000 A
6087479 Stamler et al. Jul 2000 A
6093743 Lai et al. Jul 2000 A
6095356 Rits Aug 2000 A
6105812 Riordan Aug 2000 A
6116468 Nilson Sep 2000 A
6117114 Paradis Sep 2000 A
6126640 Tucker et al. Oct 2000 A
6143318 Gilchrist et al. Nov 2000 A
6146363 Giebel et al. Nov 2000 A
6152913 Feith et al. Nov 2000 A
6158614 Haines et al. Dec 2000 A
6170522 Tanida Jan 2001 B1
6171287 Lynn et al. Jan 2001 B1
6174539 Stamler et al. Jan 2001 B1
6179141 Nakamura Jan 2001 B1
6183450 Lois Feb 2001 B1
6190364 Imbert Feb 2001 B1
6202870 Pearce Mar 2001 B1
6202901 Gerber et al. Mar 2001 B1
6206134 Stark et al. Mar 2001 B1
6207855 Toone et al. Mar 2001 B1
6227391 King May 2001 B1
6232406 Stoy May 2001 B1
6232434 Stamler et al. May 2001 B1
6237800 Barrett et al. May 2001 B1
6245056 Walker et al. Jun 2001 B1
6248380 Kocher et al. Jun 2001 B1
6250315 Ernster Jun 2001 B1
6255277 Stamler et al. Jul 2001 B1
6315113 Britton et al. Nov 2001 B1
6315761 Shcherbina et al. Nov 2001 B1
6359167 Toone et al. Mar 2002 B2
6359182 Stamler et al. Mar 2002 B1
6379660 Saavedra et al. Apr 2002 B1
6379691 Tedeschi et al. Apr 2002 B1
6394983 Mayoral et al. May 2002 B1
6402207 Segal et al. Jun 2002 B1
6403759 Stamler et al. Jun 2002 B2
6409716 Sahatjian et al. Jun 2002 B1
6444318 Guire et al. Sep 2002 B1
6468259 Djokic et al. Oct 2002 B1
6471978 Stamler et al. Oct 2002 B1
6488951 Toone et al. Dec 2002 B2
6491965 Berry et al. Dec 2002 B1
6538116 Stamler et al. Mar 2003 B2
6550493 Williamson et al. Apr 2003 B2
6555504 Ayai et al. Apr 2003 B1
6562781 Berry et al. May 2003 B1
6583311 Toone et al. Jun 2003 B2
6585691 Vitello Jul 2003 B1
6605294 Sawhney Aug 2003 B2
6605751 Gibbins et al. Aug 2003 B1
6632199 Tucker et al. Oct 2003 B1
6634498 Kayerod et al. Oct 2003 B2
6656217 Herzog, Jr. et al. Dec 2003 B1
6673891 Stamler et al. Jan 2004 B2
6679395 Pfefferkorn et al. Jan 2004 B1
6679870 Finch et al. Jan 2004 B1
6681803 Taneya et al. Jan 2004 B2
6685694 Finch et al. Feb 2004 B2
6692468 Waldenburg Feb 2004 B1
6716396 Anderson Apr 2004 B1
6725492 Moore et al. Apr 2004 B2
6786884 DeCant, Jr. et al. Sep 2004 B1
6808510 DiFiore Oct 2004 B1
6827766 Carnes et al. Dec 2004 B2
6871087 Hughes et al. Mar 2005 B1
6875840 Stamler et al. Apr 2005 B2
6880706 Braconnot et al. Apr 2005 B2
6887994 Stamler et al. May 2005 B2
6911025 Miyahar Jun 2005 B2
6929005 Sullivan et al. Aug 2005 B2
6943035 Davies et al. Sep 2005 B1
7015347 Toone et al. Mar 2006 B2
7030238 Stamler et al. Apr 2006 B2
7045585 Berry et al. May 2006 B2
7049308 Stamler et al. May 2006 B2
7052711 West et al. May 2006 B2
7056308 Utterberg Jun 2006 B2
7067659 Stamler et al. Jun 2006 B2
7081109 Tighe et al. Jul 2006 B2
7083605 Miyahara Aug 2006 B2
7087709 Stamler et al. Aug 2006 B2
7097850 Chappa et al. Aug 2006 B2
7147625 Sarangapani et al. Dec 2006 B2
7160272 Eyal et al. Jan 2007 B1
7195615 Tan Mar 2007 B2
7198611 Connell et al. Apr 2007 B2
7259250 Stamler et al. Aug 2007 B2
7279176 West et al. Oct 2007 B1
7282186 Lake, Jr. et al. Oct 2007 B2
7309326 Fangrow, Jr. Dec 2007 B2
7316669 Ranalletta Jan 2008 B2
7347853 DiFiore et al. Mar 2008 B2
7417109 Stamler et al. Aug 2008 B2
7431712 Kim Oct 2008 B2
7442402 Chudzik et al. Oct 2008 B2
7452349 Miyahar Nov 2008 B2
7485107 DiFiore et al. Feb 2009 B2
7491192 DiFiore et al. Feb 2009 B2
7516846 Hansen Apr 2009 B2
7611505 Ranalletta et al. Nov 2009 B2
7614426 Kitani et al. Nov 2009 B2
7615034 DiFiore Nov 2009 B2
7625907 Stamler et al. Dec 2009 B2
7635344 Tennican et al. Dec 2009 B2
D607325 Rogers et al. Jan 2010 S
7708714 Connell et al. May 2010 B2
7731678 Tennican et al. Jun 2010 B2
7731679 Tennican et al. Jun 2010 B2
7749189 Tennican et al. Jul 2010 B2
7753891 Tennican et al. Jul 2010 B2
7758530 DiFiore et al. Jul 2010 B2
7762524 Cawthon et al. Jul 2010 B2
7763006 Tennican Jul 2010 B2
7766182 Trent et al. Aug 2010 B2
7766897 Ramsey et al. Aug 2010 B2
7776011 Tennican et al. Aug 2010 B2
7780794 Rogers et al. Aug 2010 B2
7785616 Stamler et al. Aug 2010 B2
7794675 Lynn Sep 2010 B2
7799010 Tennican Sep 2010 B2
7815614 Fangrow, Jr. Oct 2010 B2
7857793 Raulerson et al. Dec 2010 B2
7922701 Buchman Apr 2011 B2
7922711 Ranalletta et al. Apr 2011 B2
7928079 Hrabie et al. Apr 2011 B2
7938795 DiFiore et al. May 2011 B2
7956062 Stamler et al. Jun 2011 B2
7959026 Bertani Jun 2011 B2
7963565 Suter Jun 2011 B2
7972137 Rosen Jul 2011 B2
7972322 Tennican Jul 2011 B2
7981090 Plishka et al. Jul 2011 B2
7985302 Rogers et al. Jul 2011 B2
7993309 Schweikert Aug 2011 B2
8034454 Terry Oct 2011 B2
8065773 Vaillancourt et al. Nov 2011 B2
8066670 Cluff et al. Nov 2011 B2
8069523 Vaillancourt et al. Dec 2011 B2
8113837 Zegarelli Feb 2012 B2
8146757 Abreu et al. Apr 2012 B2
8162899 Tennican Apr 2012 B2
8167847 Anderson et al. May 2012 B2
8172825 Solomon et al. May 2012 B2
8177761 Howlett et al. May 2012 B2
8197749 Howlett et al. Jun 2012 B2
8206514 Rogers et al. Jun 2012 B2
8231587 Solomon et al. Jul 2012 B2
8231602 Anderson et al. Jul 2012 B2
8252247 Ferlic Aug 2012 B2
8262628 Fangrow, Jr. Sep 2012 B2
8262643 Tennican Sep 2012 B2
8273303 Ferlic et al. Sep 2012 B2
8281824 Molema et al. Oct 2012 B2
8328767 Solomon et al. Dec 2012 B2
8336152 Kerr et al. Dec 2012 B2
8343112 Solomon et al. Jan 2013 B2
8361408 Lynn Jan 2013 B2
8372045 Needle et al. Feb 2013 B2
8377040 Burkholz et al. Feb 2013 B2
8414547 DiFiore et al. Apr 2013 B2
8419713 Solomon et al. Apr 2013 B1
8454579 Fangrow, Jr. Jun 2013 B2
8480968 Lynn Jul 2013 B2
8491546 Hoang et al. Jul 2013 B2
8500717 Becker Aug 2013 B2
8506527 Carlyon Aug 2013 B2
8506538 Chelak Aug 2013 B2
8523798 DiFiore Sep 2013 B2
8523830 Solomon et al. Sep 2013 B2
8523831 Solomon et al. Sep 2013 B2
8533887 Hirst Sep 2013 B2
8545479 Kitani et al. Oct 2013 B2
8568371 Siopes et al. Oct 2013 B2
8622995 Ziebol et al. Jan 2014 B2
8622996 Ziebol et al. Jan 2014 B2
8641681 Solomon et al. Feb 2014 B2
8641684 Utterberg et al. Feb 2014 B2
8647308 Solomon et al. Feb 2014 B2
8647326 Solomon et al. Feb 2014 B2
8651271 Shen Feb 2014 B1
8671496 Kerr et al. Mar 2014 B2
8740864 Hoang et al. Jun 2014 B2
8777504 Shaw et al. Jul 2014 B2
8791073 West et al. Jul 2014 B2
8845593 Anderson et al. Sep 2014 B2
8877231 Rosen Nov 2014 B2
8910919 Bonnal et al. Dec 2014 B2
8920404 DiFiore et al. Dec 2014 B2
8968268 Anderson et al. Mar 2015 B2
8981139 Schoenfisch et al. Mar 2015 B2
8999073 Rogers et al. Apr 2015 B2
9022984 Ziebol et al. May 2015 B2
9072296 Mills et al. Jul 2015 B2
9072868 Ziebol et al. Jul 2015 B2
9078992 Ziebol et al. Jul 2015 B2
9089680 Ueda et al. Jul 2015 B2
9095667 Von Schuckmann Aug 2015 B2
9101685 Li et al. Aug 2015 B2
9101750 Solomon et al. Aug 2015 B2
9114915 Solomon et al. Aug 2015 B2
9125600 Steube et al. Sep 2015 B2
9149624 Lewis Oct 2015 B2
9180252 Gelblum et al. Nov 2015 B2
9192449 Kerr et al. Nov 2015 B2
9205248 Wu et al. Dec 2015 B2
9216440 Ma et al. Dec 2015 B2
9242084 Solomon et al. Jan 2016 B2
9248093 Kelley, III et al. Feb 2016 B2
9248229 Devouassoux et al. Feb 2016 B2
9259284 Rogers et al. Feb 2016 B2
9259535 Anderson et al. Feb 2016 B2
9283367 Hoang et al. Mar 2016 B2
9283368 Hoang et al. Mar 2016 B2
9283369 Ma et al. Mar 2016 B2
9289588 Chen Mar 2016 B2
9296525 Murphy et al. Mar 2016 B2
9302049 Tekeste Apr 2016 B2
9320858 Grimm et al. Apr 2016 B2
9320859 Grimm et al. Apr 2016 B2
9320860 Grimm et al. Apr 2016 B2
9352080 Goodall et al. May 2016 B2
9352140 Kerr et al. May 2016 B2
9352141 Wong May 2016 B2
9352142 Ziebol et al. May 2016 B2
9381339 Wu et al. Jul 2016 B2
9399125 Burkholz Jul 2016 B2
9408971 Carlyon Aug 2016 B2
9527660 Tennican Dec 2016 B2
9592375 Tennican Mar 2017 B2
9700676 Anderson et al. Jul 2017 B2
9700677 Anderson et al. Jul 2017 B2
9700710 Anderson et al. Jul 2017 B2
9707348 Anderson et al. Jul 2017 B2
9707349 Anderson et al. Jul 2017 B2
9707350 Anderson et al. Jul 2017 B2
9809355 Solomon et al. Nov 2017 B2
9849276 Ziebol et al. Dec 2017 B2
9867975 Gardner et al. Jan 2018 B2
9907617 Rogers Mar 2018 B2
9933094 Fangrow Apr 2018 B2
9999471 Rogers et al. Jun 2018 B2
10016587 Gardner et al. Jul 2018 B2
10046156 Gardner et al. Aug 2018 B2
10159829 Ziebol et al. Dec 2018 B2
10166381 Gardner Jan 2019 B2
10195000 Rogers et al. Feb 2019 B2
10201692 Chang Feb 2019 B2
10328207 Anderson et al. Jun 2019 B2
10524982 Fangrow Jan 2020 B2
10525250 Ziebol et al. Jan 2020 B1
10695550 Gardner et al. Jun 2020 B2
10744316 Fangrow Aug 2020 B2
10806919 Gardner Oct 2020 B2
10821278 Gardner et al. Nov 2020 B2
11160932 Anderson et al. Nov 2021 B2
11229746 Anderson et al. Jan 2022 B2
11351353 Ziebol et al. Jun 2022 B2
11389634 Ziebol et al. Jul 2022 B2
11400195 Ziebol et al. Aug 2022 B2
11433215 Ziebol et al. Sep 2022 B2
11497904 Fangrow et al. Nov 2022 B2
11517732 Ziebol et al. Dec 2022 B2
11517733 Fangrow Dec 2022 B2
11534595 Ziebol et al. Dec 2022 B2
11541220 Ziebol et al. Jan 2023 B2
11541221 Ziebol et al. Jan 2023 B2
11559467 Fangrow Jan 2023 B2
11684720 Anderson et al. Jun 2023 B2
11826539 Ziebol et al. Nov 2023 B2
20020010438 Finch et al. Jan 2002 A1
20020077693 Barclay et al. Jun 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020098278 Bates et al. Jul 2002 A1
20020193752 Lynn Dec 2002 A1
20030039697 Zhao et al. Feb 2003 A1
20030060749 Aneas Mar 2003 A1
20030062376 Sears et al. Apr 2003 A1
20030072783 Stamler et al. Apr 2003 A1
20030153865 Connell et al. Aug 2003 A1
20030199835 Leinsing et al. Oct 2003 A1
20040034042 Tsuji et al. Feb 2004 A1
20040034329 Mankus et al. Feb 2004 A1
20040037836 Stamler et al. Feb 2004 A1
20040048542 Thomaschefsky et al. Mar 2004 A1
20040052689 Yao Mar 2004 A1
20040052831 Modak et al. Mar 2004 A1
20040156908 Polaschegg et al. Aug 2004 A1
20040210201 Farnan Oct 2004 A1
20040215148 Hwang et al. Oct 2004 A1
20040247640 Zhao et al. Dec 2004 A1
20040249337 DiFiore Dec 2004 A1
20040249338 DeCant, Jr. et al. Dec 2004 A1
20040258560 Lake, Jr. et al. Dec 2004 A1
20050013836 Raad Jan 2005 A1
20050065479 Schiller et al. Mar 2005 A1
20050098527 Yates et al. May 2005 A1
20050124970 Kunin et al. Jun 2005 A1
20050147524 Bousquet Jul 2005 A1
20050147525 Bousquet Jul 2005 A1
20050148930 Hseih et al. Jul 2005 A1
20050152891 Toone et al. Jul 2005 A1
20050171493 Nicholls Aug 2005 A1
20050203460 Kim Sep 2005 A1
20050214185 Castaneda Sep 2005 A1
20050220882 Pritchard et al. Oct 2005 A1
20050228482 Herzog et al. Oct 2005 A1
20050256461 DiFiore et al. Nov 2005 A1
20050265958 West et al. Dec 2005 A1
20050267421 Wing Dec 2005 A1
20050271711 Lynch et al. Dec 2005 A1
20050288551 Callister et al. Dec 2005 A1
20060004316 DiFiore et al. Jan 2006 A1
20060024372 Utterberg et al. Feb 2006 A1
20060030827 Raulerson et al. Feb 2006 A1
20060096348 DiFiore May 2006 A1
20060118122 Martens et al. Jun 2006 A1
20060149191 DiFiore Jul 2006 A1
20060195117 Rucker et al. Aug 2006 A1
20060206178 Kim Sep 2006 A1
20060261076 Anderson Nov 2006 A1
20070003603 Karandikar et al. Jan 2007 A1
20070106205 Connell et al. May 2007 A1
20070112333 Hoang et al. May 2007 A1
20070156118 Ramsey et al. Jul 2007 A1
20070167910 Tennican et al. Jul 2007 A1
20070176117 Redmond et al. Aug 2007 A1
20070187353 Fox et al. Aug 2007 A1
20070212381 DiFiore et al. Sep 2007 A1
20070231315 Lichte et al. Oct 2007 A1
20070248676 Stamler et al. Oct 2007 A1
20070249996 Tennican et al. Oct 2007 A1
20070265578 Tennican et al. Nov 2007 A1
20070282280 Tennican Dec 2007 A1
20070287989 Crawford et al. Dec 2007 A1
20080019889 Rogers et al. Jan 2008 A1
20080027399 Harding et al. Jan 2008 A1
20080027401 Ou-Yang Jan 2008 A1
20080033371 Updegraff et al. Feb 2008 A1
20080039803 Lynn Feb 2008 A1
20080058733 Vogt et al. Mar 2008 A1
20080086091 Anderson et al. Apr 2008 A1
20080093245 Periasamy et al. Apr 2008 A1
20080095680 Steffens et al. Apr 2008 A1
20080097315 Miner et al. Apr 2008 A1
20080097407 Plishka Apr 2008 A1
20080287920 Fangrow et al. May 2008 A1
20080014005 Shirley Jun 2008 A1
20080128646 Clawson Jun 2008 A1
20080132880 Buchman Jun 2008 A1
20080147047 Davis et al. Jun 2008 A1
20080161763 Harding et al. Jul 2008 A1
20080172007 Bousquet Jul 2008 A1
20080173651 Ping Jul 2008 A1
20080177250 Howlett et al. Jul 2008 A1
20080187460 Utterberg et al. Aug 2008 A1
20080188791 DiFiore et al. Aug 2008 A1
20080235888 Vaillancourt et al. Oct 2008 A1
20080262465 Zinger et al. Oct 2008 A1
20080318333 Nielsen et al. Dec 2008 A1
20080319423 Tanghoj et al. Dec 2008 A1
20090008393 Howlett et al. Jan 2009 A1
20090012426 Tennican Jan 2009 A1
20090024096 Hai et al. Jan 2009 A1
20090028750 Ryan Jan 2009 A1
20090062766 Howlett et al. Mar 2009 A1
20090093757 Tennican Apr 2009 A1
20090099529 Anderson Apr 2009 A1
20090126867 Decant, Jr. et al. May 2009 A1
20090137969 Colantonio et al. May 2009 A1
20090149820 DiFiore Jun 2009 A1
20090163876 Chebator et al. Jun 2009 A1
20090205151 Fisher et al. Aug 2009 A1
20090205656 Nishibayashi et al. Aug 2009 A1
20090247485 Ahmed et al. Oct 2009 A1
20090259194 Pinedjian et al. Oct 2009 A1
20090270832 Vancaillie et al. Oct 2009 A1
20090293882 Terry Dec 2009 A1
20100003067 Shaw et al. Jan 2010 A1
20100004510 Kuroshima Jan 2010 A1
20100047123 Solomon et al. Feb 2010 A1
20100049170 Solomon et al. Feb 2010 A1
20100050351 Colantonio Mar 2010 A1
20100059474 Brandenburger et al. Mar 2010 A1
20100064456 Ferlic Mar 2010 A1
20100074932 Talsma Mar 2010 A1
20100106102 Ziebol et al. Apr 2010 A1
20100106103 Ziebol et al. Apr 2010 A1
20100137472 Ou-Yang Jun 2010 A1
20100143427 King et al. Jun 2010 A1
20100152670 Low Jun 2010 A1
20100160894 Julian et al. Jun 2010 A1
20100172794 Ferlic et al. Jul 2010 A1
20100242993 Hoang et al. Sep 2010 A1
20100253070 Cheon et al. Oct 2010 A1
20100280805 DiFiore Nov 2010 A1
20100292673 Korogi et al. Nov 2010 A1
20100292674 Jepson et al. Nov 2010 A1
20100306938 Rogers et al. Dec 2010 A1
20100318040 Kelley, III et al. Dec 2010 A1
20110030726 Vaillancourt et al. Feb 2011 A1
20110044850 Solomon et al. Feb 2011 A1
20110046564 Zhong Feb 2011 A1
20110046603 Felsovalyi et al. Feb 2011 A1
20110062703 Lopez Mar 2011 A1
20110064512 Shaw et al. Mar 2011 A1
20110071475 Horvath et al. Mar 2011 A1
20110082431 Burgess et al. Apr 2011 A1
20110150958 Davis et al. Jun 2011 A1
20110184338 McKay Jul 2011 A1
20110184382 Cady Jul 2011 A1
20110208128 Wu et al. Aug 2011 A1
20110217212 Solomon et al. Sep 2011 A1
20110232020 Rogers et al. Sep 2011 A1
20110265825 Rogers et al. Nov 2011 A1
20110276031 Hoang et al. Nov 2011 A1
20110277788 Rogers et al. Nov 2011 A1
20110282302 Lopez et al. Nov 2011 A1
20110290799 Anderson et al. Dec 2011 A1
20110311602 Mills et al. Dec 2011 A1
20110314619 Schweikert Dec 2011 A1
20120022469 Albert et al. Jan 2012 A1
20120029483 Griffith et al. Feb 2012 A1
20120031904 Kuhn et al. Feb 2012 A1
20120039764 Solomon et al. Feb 2012 A1
20120083730 Rush et al. Apr 2012 A1
20120083750 Sansoucy Apr 2012 A1
20120157965 Wotton et al. Jun 2012 A1
20120191029 Hopf et al. Jul 2012 A1
20120191067 Chia et al. Jul 2012 A1
20120195807 Ferlic Aug 2012 A1
20120216359 Rogers et al. Aug 2012 A1
20120216360 Rogers et al. Aug 2012 A1
20120220955 Maseda et al. Aug 2012 A1
20120283693 Anderson et al. Nov 2012 A1
20120283696 Cronenberg et al. Nov 2012 A1
20120296284 Anderson et al. Nov 2012 A1
20120302968 Tennican Nov 2012 A1
20120302970 Tennican Nov 2012 A1
20120302997 Gardner et al. Nov 2012 A1
20120315201 Ferlic et al. Dec 2012 A1
20130030414 Gardner et al. Jan 2013 A1
20130035667 Anderson et al. Feb 2013 A1
20130039953 Dudnyk et al. Feb 2013 A1
20130053751 Holtham Feb 2013 A1
20130072908 Solomon et al. Mar 2013 A1
20130085313 Fowler et al. Apr 2013 A1
20130085474 Charles et al. Apr 2013 A1
20130098398 Kerr et al. Apr 2013 A1
20130098938 Efthimiadis Apr 2013 A1
20130102950 DiFiore Apr 2013 A1
20130123754 Solomon et al. May 2013 A1
20130134161 Fogel et al. May 2013 A1
20130138085 Tennican May 2013 A1
20130144258 Ziebol et al. Jun 2013 A1
20130150795 Snow Jun 2013 A1
20130164189 Hadden Jun 2013 A1
20130171030 Ferlic et al. Jul 2013 A1
20130183635 Wilhoit Jul 2013 A1
20130184679 Ziebol et al. Jul 2013 A1
20130204231 Ziebol et al. Aug 2013 A1
20130274686 Ziebol et al. Oct 2013 A1
20140034540 Solomon et al. Feb 2014 A1
20140042116 Shen et al. Feb 2014 A1
20140048079 Gardner et al. Feb 2014 A1
20140052074 Tekeste Feb 2014 A1
20140101876 Rogers et al. Apr 2014 A1
20140148781 Tekeste May 2014 A1
20140155868 Nelson et al. Jun 2014 A1
20140227144 Liu et al. Aug 2014 A1
20140228775 Burkholz et al. Aug 2014 A1
20140228809 Wong Aug 2014 A1
20140243797 Jensen et al. Aug 2014 A1
20140336610 Michel et al. Nov 2014 A1
20150018774 Anderson et al. Jan 2015 A1
20150086441 She et al. Mar 2015 A1
20150165127 Haefele et al. Jun 2015 A1
20150217106 Banik et al. Aug 2015 A1
20150237854 Mills et al. Aug 2015 A1
20150238703 Glocker Aug 2015 A1
20150258324 Chida et al. Sep 2015 A1
20150298893 Welp Oct 2015 A1
20150306367 DiFiore Oct 2015 A1
20150314119 Anderson et al. Nov 2015 A1
20150314120 Gardner et al. Nov 2015 A1
20150320926 Fitzpatrick et al. Nov 2015 A1
20150320992 Bonnet et al. Nov 2015 A1
20150343174 Ziebol et al. Dec 2015 A1
20150374968 Solomon et al. Dec 2015 A1
20160001056 Nelson et al. Jan 2016 A1
20160001058 Ziebol et al. Jan 2016 A1
20160015863 Gupta et al. Jan 2016 A1
20160015931 Ryan et al. Jan 2016 A1
20160015959 Solomon et al. Jan 2016 A1
20160045629 Gardner et al. Feb 2016 A1
20160067365 Ma et al. Mar 2016 A1
20160067471 Ingram et al. Mar 2016 A1
20160088995 Ueda et al. Mar 2016 A1
20160089530 Sathe Mar 2016 A1
20160101223 Kelley, III et al. Apr 2016 A1
20160101276 Tekeste Apr 2016 A1
20160106969 Neftel Apr 2016 A1
20160121097 Steele May 2016 A1
20160144118 Solomon et al. May 2016 A1
20160158520 Ma et al. Jun 2016 A1
20160158521 Hoang et al. Jun 2016 A1
20160158522 Hoang et al. Jun 2016 A1
20160184527 Tekeste Jun 2016 A1
20160213912 Daneluzzi Jul 2016 A1
20160220790 Borowicz Aug 2016 A1
20160250420 Maritan et al. Sep 2016 A1
20160354596 DiFiore Dec 2016 A1
20170020911 Berry et al. Jan 2017 A1
20170042636 Young Feb 2017 A1
20170143447 Rogers et al. May 2017 A1
20170182241 DiFiore Jun 2017 A1
20170203092 Ryan et al. Jul 2017 A1
20170239443 Abitabilo et al. Aug 2017 A1
20170361023 Anderson et al. Dec 2017 A1
20180200500 Ziebol et al. Jul 2018 A1
20180214684 Avula et al. Aug 2018 A1
20180369562 Gardner Dec 2018 A1
20190038888 Gardner Feb 2019 A1
20190111245 Gardner et al. Apr 2019 A1
20190282795 Fangrow Sep 2019 A1
20190351211 Dombrowski et al. Nov 2019 A1
20200139037 Ziebol et al. May 2020 A1
20200139102 Ziebol et al. May 2020 A1
20200139103 Ziebol et al. May 2020 A1
20200139104 Ziebol et al. May 2020 A1
20200324102 Fangrow Oct 2020 A1
20200330741 Fangrow Oct 2020 A1
20200406020 Fangrow Dec 2020 A1
20210093791 Anderson Apr 2021 A1
20210106805 Fangrow Apr 2021 A1
20210162194 Gardner Jun 2021 A1
20210205596 Ziebol et al. Jul 2021 A1
20210308442 Gardner Oct 2021 A1
20220226629 Ziebel Jul 2022 A1
20220288258 Gardner Sep 2022 A1
20220288376 Ziebol Sep 2022 A1
20220313977 Gugel et al. Oct 2022 A1
20220379035 Anderson Dec 2022 A1
20220387685 Ziebol Dec 2022 A1
20230069367 Ziebol Mar 2023 A1
20230105566 Fangrow Apr 2023 A1
20230121450 Ziebol Apr 2023 A1
20230285735 Ziebol Sep 2023 A1
20230288258 Gardner Sep 2023 A1
20240050729 Ziebol Feb 2024 A1
20240050730 Fangrow Feb 2024 A1
Foreign Referenced Citations (144)
Number Date Country
2 148 847 Dec 1995 CA
2 169 689 Aug 1996 CA
2 583 601 Apr 2006 CA
2825217 Mar 2007 CA
2 626 864 May 2007 CA
2 651 192 Nov 2007 CA
2 615 146 Jun 2008 CA
2 841 832 Jun 2019 CA
2402327 Oct 2000 CN
2815392 Sep 2006 CN
201150420 Nov 2008 CN
201519335 Jul 2010 CN
106902402 Jun 2017 CN
107837428 Mar 2018 CN
3515665 May 1986 DE
89 06 628 Sep 1989 DE
43 34 272 Apr 1995 DE
29617133 Jan 1997 DE
102007025900 Dec 2008 DE
0 063 640 Nov 1982 EP
0 088 341 Sep 1983 EP
0 108 785 May 1984 EP
0 174 162 Mar 1986 EP
0 227 219 Jul 1987 EP
0 237 239 Sep 1987 EP
0 245 872 Nov 1987 EP
0 257 485 Mar 1988 EP
0 639 385 Feb 1995 EP
0 734 721 Oct 1996 EP
0 769 265 Apr 1997 EP
1 061 000 Oct 2000 EP
1 331 020 Jul 2003 EP
1 471 011 Oct 2004 EP
1 442 753 Feb 2007 EP
1 813 293 Aug 2007 EP
1 977 714 Oct 2008 EP
2 444 117 Apr 2012 EP
2 606 930 Jun 2013 EP
2 671 604 Dec 2013 EP
2 731 658 May 2014 EP
2 493 149 May 1982 FR
2 506 162 Nov 1982 FR
2 782 910 Mar 2000 FR
123221 Feb 1919 GB
2 296 182 Jun 1996 GB
2 333 097 Jul 1999 GB
2 387 772 Oct 2003 GB
57-131462 Aug 1982 JP
04-99950 Feb 1992 JP
05-31180 Feb 1993 JP
09-216661 Aug 1997 JP
2000-157630 Jun 2000 JP
2002-210011 Jul 2002 JP
2002-234567 Aug 2002 JP
2002-291906 Oct 2002 JP
2005-218649 Aug 2005 JP
2006-182663 Jul 2006 JP
2006-223583 Aug 2006 JP
2009-006148 Jan 2009 JP
2011-036691 Feb 2011 JP
2011-528647 Nov 2011 JP
2012-020125 Feb 2012 JP
2013-520287 Jun 2013 JP
2014-117461 Jun 2014 JP
2 246 321 Feb 2005 RU
WO 198303975 Nov 1983 WO
WO 198505040 Nov 1985 WO
WO 9320806 Oct 1993 WO
WO 9507691 Mar 1995 WO
WO 9635416 Nov 1996 WO
WO 9638136 Dec 1996 WO
WO 199719701 Jun 1997 WO
WO 199812125 Mar 1998 WO
WO 199848872 Nov 1998 WO
WO 199944665 Sep 1999 WO
WO 200170199 Sep 2001 WO
WO 200205188 Jan 2002 WO
WO 200247581 Jun 2002 WO
WO 200249544 Jun 2002 WO
WO 2003015677 Feb 2003 WO
WO 2003070296 Aug 2003 WO
WO 2004035129 Apr 2004 WO
WO 2004112846 Dec 2004 WO
WO 2005112954 Dec 2005 WO
WO 2005112974 Dec 2005 WO
WO 2006007690 Jan 2006 WO
WO 2006044236 Apr 2006 WO
WO 2006102756 Oct 2006 WO
WO 2007056773 May 2007 WO
WO 2007137056 Nov 2007 WO
WO 2008014437 Jan 2008 WO
WO 2008042285 Apr 2008 WO
WO 2008086631 Jul 2008 WO
WO 2008089196 Jul 2008 WO
WO 2008100950 Aug 2008 WO
WO 2008140807 Nov 2008 WO
WO 2009002474 Dec 2008 WO
WO 2009060322 May 2009 WO
WO 2009117135 Sep 2009 WO
WO 2009123709 Oct 2009 WO
WO 2009136957 Nov 2009 WO
WO 2009153224 Dec 2009 WO
WO 2010002757 Jan 2010 WO
WO 2010002808 Jan 2010 WO
WO 2010011616 Jan 2010 WO
WO 2010034470 Apr 2010 WO
WO 2010039171 Apr 2010 WO
WO 2010062589 Jun 2010 WO
WO 2011012379 Feb 2011 WO
WO 2011028722 Mar 2011 WO
WO 2011053924 May 2011 WO
WO 2011106374 Sep 2011 WO
WO 2011119021 Sep 2011 WO
WO 2012118829 Sep 2012 WO
WO 2012162006 Nov 2012 WO
WO 2013009998 Jan 2013 WO
WO 2013023146 Feb 2013 WO
WO 2013082180 Jun 2013 WO
WO 2012184716 Dec 2013 WO
WO 2013192574 Dec 2013 WO
WO 2014031628 Feb 2014 WO
WO 2014074929 May 2014 WO
WO 2014126867 Aug 2014 WO
WO 2014140949 Sep 2014 WO
WO 2014159346 Oct 2014 WO
WO 2015119940 Aug 2015 WO
WO 2015120336 Aug 2015 WO
WO 2015164129 Oct 2015 WO
WO 2015164134 Oct 2015 WO
WO 2015168677 Nov 2015 WO
WO 2015174953 Nov 2015 WO
WO 2016182822 Nov 2016 WO
WO 2017127364 Jul 2017 WO
WO 2017127365 Jul 2017 WO
WO 2018009653 Jan 2018 WO
WO 2018071717 Apr 2018 WO
WO 2018204206 Nov 2018 WO
WO 2018237090 Dec 2018 WO
WO 2018237122 Dec 2018 WO
WO 2019178560 Sep 2019 WO
WO 2019246472 Dec 2019 WO
WO 2020097366 May 2020 WO
WO 2020251947 Dec 2020 WO
WO 2022125474 Jun 2022 WO
Non-Patent Literature Citations (97)
Entry
“Small-bore connectors for liquids and gases in healthcare applications—Part : Connectors for intravascular or hypodermic applications,” ISO 80369-7, Corrected version dated Dec. 1, 2016 (50 pages).
Australian Examination Report re AU Application No. 2008269133, dated Aug. 27, 2012 (4 pages).
Australian Examination Report (No. 2) re AU Application No. 2008269133, dated Jan. 9, 2013 (3 pages).
Australian Examination Report (No. 3) re AU Application No. 2008269133, dated May 1, 2013 (3 pages).
Australian Examination Report (Notice of Acceptance) re AU Application No. 2008269133, dated Nov. 14, 2013 (2 pages).
Australian Examination Report re AU Application No. 2012258435, dated Apr. 18, 2013 (4 pages).
Australian Examination Report re AU Application No. 2013100345, dated Apr. 18, 2013 (4 pages).
Australian Examination Report re AU Application No. 2013224680, dated May 19, 2015 (2 pages).
Baxter Minicap: Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages).
Baxter, “Peritoneal Dialysis Patient Connectology,” Product Descriptions in 1 page, downloaded Jul. 1, 2011.
Canadian Examination Report, re CA Application No. 2,692,157, dated Apr. 27, 2011 (2 pages).
Canadian Examination Report, re CA Application No. 2,692,157, dated Jun. 6, 2011 (2 pages).
Canadian Examination Report, re CA Application No. 2,692,157, dated Jan. 23, 2013 (4 pages).
Canadian Notice of Allowance, re CA Application No. 2,692,157, dated Oct. 2, 2013 (4 pages).
Canadian Examination Report, re CA Application No. 2,846,145, dated Apr. 30, 2015 (3 pages).
Catheter Connections, “Introducing DualCap,” Product Brochure in 1 page, Copyright 2011.
Charney, “Baxter Healthcare InterlinkTM IV Access System” in 1 page, from Handbook of Modern Hospital Safety. Published Mar. 1999.
Chinese Office Action, re CN Application No. 200880103854.5, dated Aug. 3, 2011 (5 pages).
Chinese Second Office Action, re CN Application No. 200880103854.5, dated Apr. 16, 2012 (4 pages).
Chinese Third Office Action, re CN Application No. 200880103854.5, dated Nov. 1, 2012 (4 pages).
Chinese Office Action, re CN Application No. 201310087320.0, dated May 4, 2014 (20 pages).
Colombian Office Action, re CO Application No. 10.000.937, dated Oct. 2012 (9 pages).
Colombian Office Action, re CO Application No. 14.094.083, dated Jul. 2015 (13 pages).
Conical Fittings: International Standard, “Conical fittings with 6% (Luer) Taper for Syringes, Needles and certain Other Medical Equipment—Part 2: Lock Fittings”, Ref. No. ISO 594-2:1998. International Organization for Standardization (Sep. 1, 1998) 2nd ed. (16 pages).
Devine, redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 16, 2011 (3 pages).
Devine, redacted version of letter from David A. Divine, Esq. of Lee & Hayes, dated May 27, 2011 (3 pages).
Hospira, “You Work in Neverland,” Lifeshield Product Brochure in 2 pages, Published 2009.
Hyprotek, “Port Protek,” Product Brochure in 1 page, downloaded Sep. 19, 2011 from http://www.hyprotek.com/products.html.
ICU Medical Inc., “Oncology System Solutions,” Product Brochure in 17 pages, Copyright 2013.
ICU Medical Inc., “Protective Cap,” Photographs of Spiros Protective Cap in 2 pages, Product available 2013.
International Written Opinion re PCT/US08/07797, dated Sep. 11, 2008 (3 pages).
International Preliminary Report on Patentability re PCT/US08/07797, dated Dec. 22, 2009 (4 pages).
International Search Report re PCT/US2012/037772, dated Oct. 26, 2012 (5 pages).
International Written Opinion re PCT/US2012/037772, dated Oct. 26, 2012 (5 pages).
International Preliminary Report on Patentability re PCT/US2012/037772, dated Nov. 26, 2012 (7 pages).
International Search Report re PCT/US2012/038880, dated Nov. 19, 2012 (5 pages).
International Written Opinion re PCT/US2012/038880, dated Nov. 19, 2012 (8 pages).
International Preliminary Report on Patentability re PCT/US2012/038880, dated Nov. 20, 2013 (1 pages).
International Search Report re PCT/US2012/062078, dated Feb. 14, 2013 (3 pages).
International Written Opinion re PCT/US2012/062078, dated Feb. 14, 2013 (3 pages).
International Preliminary Report on Patentability re PCT/US2012/062078, dated May 6, 2014 (3 pages).
International Search Report re PCT/US2014/23140, dated Jul. 28, 2014 (3 pages).
International Written Opinion re PCT/US2014/23140, dated Jul. 28, 2014 (6 pages).
Japanese Office Action, re JP Application No. 2013-162527, dated Nov. 21, 2014 (2 pages).
Japanese Final Office Action, re JP Application No. 2010-163450, dated Apr. 3, 2015 (9 pages).
Menyhay et al., “Disinfection of Needleless Catheter Connectors and Access Ports with Alcohol May Not Prevent Microbial Entry: The Promise of a Novel Antiseptic-Barrier Cap” Infection Control Hospital and Epidemiology, vol. 27, No. 1 (Jan. 2006) (5 pages).
Mexican Office Action (Memo [2nd] concerning OA) re MX Application No. MX/a/2010/000171, Oct. 22, 2013 (1 pages).
Mexican Office Action (Memo concerning OA) re MX Application No. MX/a/2010/000171, Feb. 25, 2013 (2 pages).
New Zealand Examination Report and Notice of Acceptance, re NZ Application No. 582395, dated Jun. 13, 2011 (2 pages).
New Zealand Examination Report, re NZ Application No. 582395, dated Nov. 8, 2012 (2 pages).
New Zealand Examination Report and Notice of Acceptance, re NZ Application No. 582395, dated Dec. 5, 2012 (1 page).
New Zealand Examination Report re NZ Application No. 603404, dated Nov. 8, 2012 (2 pages).
New Zealand Examination Report (1st) re NZ Application No. 623139, dated Apr. 8, 2014 (1 pages).
New Zealand Examination Report (1st) re NZ Application No. 623141, dated Apr. 9, 2014 (1 pages).
New Zealand Examination Report (1st) re NZ Application No. 624449, dated Dec. 5, 2014 (2 pages).
Photographs of the Baxter Minicap (Sep. 1, 1998) (4 pages).
U.S. Office Action, re U.S. Appl. No. 11/821,190, dated Dec. 17, 2009 (10 pages).
U.S. Office Action, re U.S. Appl. No. 11/821,190, dated Aug. 2, 2010 (14 pages).
U.S. Interview Summary, re U.S. Appl. No. 11/821,190, dated Nov. 18, 2010 (4 pages).
U.S. Office Action, re U.S. Appl. No. 11/821,190, dated Mar. 7, 2011 (16 pages).
U.S. Office Action/Notice of Allowance, re U.S. Appl. No. 11/821,190, dated Apr. 26, 2011 (9 pages).
U.S. Notice of Allowance, re U.S. Appl. No. 11/821,190, dated Jul. 29, 2011 (6 pages).
U.S. Office Action, re U.S. Appl. No. 12/214,526, dated Jun. 9, 2011 (7 pages).
U.S. Final Office Action, re U.S. Appl. No. 12/214,526, dated Oct. 31, 2011 (8 pages).
U.S. Interview Summary, re U.S. Appl. No. 12/214,526, dated Mar. 23, 2012 (3 pages).
U.S. Office Action, re U.S. Appl. No. 13/095,516, dated Dec. 21, 2011 (27 pages).
U.S. Office Action/Notice of Allowance, re U.S. Appl. No. 13/095,516, dated May 16, 2012 (18 pages).
U.S. Office Action/Non-Final, re U.S. Appl. No. 13/113,777, dated Dec. 3, 2013 (13 pages).
U.S. Office Action/Final, re U.S. Appl. No. 13/113,777, dated Aug. 25, 2014 (9 pages).
U.S. Office Action/Final, re U.S. Appl. No. 13/113,777, dated Apr. 3, 2015 (9 pages).
U.S. Office Action, re U.S. Appl. No. 13/288,529, dated Apr. 8, 2015 (12 pages).
U.S. Office Action/Non-Final, re U.S. Appl. No. 13/456,853, dated Dec. 14, 2012 (16 pages).
U.S. Office Action/Final, re U.S. Appl. No. 13/456,853, dated Aug. 27, 2013 (18 pages).
U.S. Office Action, re U.S. Appl. No. 13/456,853, dated Mar. 27, 2014 (14 pages).
U.S. Office Action/Notice of Allowance, re U.S. Appl. No. 13/456,853, dated Dec. 3, 2014 (9 pages).
U.S. Office Action, re U.S. Appl. No. 13/473,057, dated Feb. 8, 2013 (20 pages).
U.S. Office Action/Final, re U.S. Appl. No. 13/473,057, dated Dec. 3, 2013 (19 pages).
U.S. Office Action, re U.S. Appl. No. 13/476,722, dated Jun. 24, 2015 (10 pages).
U.S. Office Action, re U.S. Appl. No. 13/547,650, dated Jan. 29, 2015 (9 pages).
U.S Office Action, re U.S. Appl. No. 13/560,499, dated Feb. 11, 2015 (9 pages).
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated May 3, 2013 (15 pages).
U.S. Office Action/Final, re U.S. Appl. No. 13/649,569, dated Aug. 23, 2013 (19 pages).
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated Apr. 14, 2014 (27 pages).
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated Jan. 29, 2015 (14 pages).
U.S. Office Action, re U.S. Appl. No. 13/649,569, dated Sep. 28, 2015 (17 pages).
Antibiotic Lock Therapy Guideline, Stanford Hospital and Clinics, Pharmacy Department Policies and Procedures, issued Jun. 2011.
Otto, Mosby's Pocket Guide to Infusion Therapy. Elsevier Health Sciences, 2004. pp. 65-66. Accessed at: http://books.google.com/books?id=j8T14HwWdS4C&lpg=PP1&pg=PP1#v=onepage&f=false (Year: 2004).
Clave® Needlefree Connector, icumedical, human connections, 2 page brochure. 2012, M1-1065 Rev. 04.
Du. Y, et al. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex, Journal of Biomedical Materials Research Part A, 2006, 216-225.
Holmer, E. et al. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor XIIa and kallikrein by antithrombin, Biochem. J. (1981) 193, 395-400.
ICU Medical Antimicrobial Microclave, first sold Jan. 21, 2010, p. 1-2.
Klement, P. et al. Chronic performance of polyurethane catheters covalently coated with ATH complex: A rabbit jugular vein model, Biomaterials, (2006), 27, 5107-5117.
Thread Check Inc., ISO 80369-7 replaces ISO 594-2:1998€, retrieved 2023; ISO 80369-7 published Oct. 2016, https://www.threadcheck.com/isl-80369/technicalinfo#gref (Year: 2016).
V-Link Luer Activated Device, with VitalShield Protective Coating, 2 page brochure, Baxter Dec. 2009.
U.S. Appl. No. 16/882,210, filed May 22, 2020.
Value Plastics, Inc., “Finger Snap Luer Lock Ring (FSLLR),” drawn by Frank Lombardi, May 29, 2011.
ICU Medical SwabPack, top-access bag of disinfecting caps for needlefree connectors, on sale at least as early as Jan. 2012.
Related Publications (1)
Number Date Country
20210162194 A1 Jun 2021 US
Continuations (2)
Number Date Country
Parent 16162106 Oct 2018 US
Child 17025201 US
Parent 13803289 Mar 2013 US
Child 16162106 US
Continuation in Parts (1)
Number Date Country
Parent 13113777 May 2011 US
Child 13803289 US